Last 12 months
Inside the activity.
0 purchase rows · 28 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 7 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 13 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2021 Filed Sep 20, 2021 21:30 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 432 | $29.06 | $12,553.92 |
DisclosureSEC source: 0001209191-21-056913 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,551 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.14 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 16, 2021 Filed Sep 20, 2021 21:31 UTC |
UBS Oncology Impact Fund L.P.10% owner
MPM BIOIMPACT LLC10% owner
|
SaleCommon Stock | 3,124 | $29.06 | $90,783.44 |
DisclosureSEC source: 0001209191-21-056914 · doc4.xml · nonDerivative · entry 1 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,648,268 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.14 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| September 16, 2021 Filed Mar 25, 2022 23:32 UTC |
GADICKE ANSBERTDirector · 10% owner
|
GrantStock Option (Right to Buy) · Derivative | 7,800 | $0.00 Strike: $28.80 | $0.00 |
DisclosureSEC source: 0000899243-22-012375 · doc4.xml · derivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2031-09-15 F1 · derivative.exercise_date: The option represents a right to purchase a total of 7,800 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 25, 2022 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date. Read SEC document |
| September 16, 2021 Filed Mar 25, 2022 23:34 UTC |
Rosenberg AnthonyDirector
|
GrantStock Option (Right to Buy) · Derivative | 7,800 | $0.00 Strike: $28.80 | $0.00 |
DisclosureSEC source: 0000899243-22-012378 · doc4.xml · derivative · entry 1 Rosenberg Anthony · CIK 0001466175 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2031-09-15 F1 · derivative.exercise_date: The option represents a right to purchase a total of 7,800 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 25, 2022 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date. Read SEC document |
| September 16, 2021 Filed Mar 25, 2022 23:33 UTC |
Webster Stephen WDirector
|
GrantStock Option (Right to Buy) · Derivative | 7,800 | $0.00 Strike: $28.80 | $0.00 |
DisclosureSEC source: 0000899243-22-012376 · doc4.xml · derivative · entry 1 Webster Stephen W · CIK 0001438421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2031-09-15 F1 · derivative.exercise_date: The option represents a right to purchase a total of 7,800 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 25, 2022 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date. Read SEC document |
| September 16, 2021 Filed Mar 25, 2022 19:35 UTC |
Ebeling ThomasDirector
|
GrantStock Option (Right to Buy) · Derivative | 7,800 | $0.00 Strike: $28.80 | $0.00 |
DisclosureSEC source: 0000899243-22-012380 · doc4.xml · derivative · entry 1 Ebeling Thomas · CIK 0001297759 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2031-09-15 F1 · derivative.exercise_date: The option represents a right to purchase a total of 7,800 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 25, 2022 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date. Read SEC document |
| September 16, 2021 Filed Mar 25, 2022 23:32 UTC |
Jovan-Embiricos MoranaDirector
|
GrantStock Option (Right to Buy) · Derivative | 7,800 | $0.00 Strike: $28.80 | $0.00 |
DisclosureSEC source: 0000899243-22-012373 · doc4.xml · derivative · entry 1 Jovan-Embiricos Morana · CIK 0001575745 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2031-09-15 F1 · derivative.exercise_date: The option represents a right to purchase a total of 7,800 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 25, 2022 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 20:44 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 6,425 | $29.16 | $187,353.00 |
DisclosureSEC source: 0001209191-21-056409 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,651,392 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.43 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 20:44 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 888 | $29.16 | $25,894.08 |
DisclosureSEC source: 0001209191-21-056409 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,983 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.43 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 20:45 UTC |
UBS Oncology Impact Fund L.P.10% owner
MPM BIOIMPACT LLC10% owner
|
SaleCommon Stock | 6,425 | $29.16 | $187,353.00 |
DisclosureSEC source: 0001209191-21-056411 · doc4.xml · nonDerivative · entry 2 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,651,392 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.43 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 20:44 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 7,106 | $29.17 | $207,282.02 |
DisclosureSEC source: 0001209191-21-056409 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,657,817 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 20:44 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 982 | $29.17 | $28,644.94 |
DisclosureSEC source: 0001209191-21-056409 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,871 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 20:45 UTC |
UBS Oncology Impact Fund L.P.10% owner
MPM BIOIMPACT LLC10% owner
|
SaleCommon Stock | 7,106 | $29.17 | $207,282.02 |
DisclosureSEC source: 0001209191-21-056411 · doc4.xml · nonDerivative · entry 1 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,657,817 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| September 13, 2021 Filed Sep 13, 2021 22:22 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 3,595 | $29.10 | $104,614.50 |
DisclosureSEC source: 0001209191-21-055725 · doc4.xml · nonDerivative · entry 6 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,664,923 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 13, 2021 Filed Sep 13, 2021 22:22 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 497 | $29.10 | $14,462.70 |
DisclosureSEC source: 0001209191-21-055725 · doc4.xml · nonDerivative · entry 5 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,853 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 13, 2021 Filed Sep 13, 2021 22:24 UTC |
UBS Oncology Impact Fund L.P.10% owner
MPM BIOIMPACT LLC10% owner
|
SaleCommon Stock | 3,595 | $29.10 | $104,614.50 |
DisclosureSEC source: 0001209191-21-055726 · doc4.xml · nonDerivative · entry 3 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,664,923 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 22:22 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 5,931 | $29.04 | $172,236.24 |
DisclosureSEC source: 0001209191-21-055725 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,668,518 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.105 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 22:22 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 820 | $29.04 | $23,812.80 |
DisclosureSEC source: 0001209191-21-055725 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,350 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.105 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 22:24 UTC |
UBS Oncology Impact Fund L.P.10% owner
MPM BIOIMPACT LLC10% owner
|
SaleCommon Stock | 5,931 | $29.04 | $172,236.24 |
DisclosureSEC source: 0001209191-21-055726 · doc4.xml · nonDerivative · entry 2 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,668,518 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.105 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 22:22 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 13,727 | $29.35 | $402,887.45 |
DisclosureSEC source: 0001209191-21-055725 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,674,449 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 22:22 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 1,898 | $29.35 | $55,706.30 |
DisclosureSEC source: 0001209191-21-055725 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,170 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 22:24 UTC |
UBS Oncology Impact Fund L.P.10% owner
MPM BIOIMPACT LLC10% owner
|
SaleCommon Stock | 13,727 | $29.35 | $402,887.45 |
DisclosureSEC source: 0001209191-21-055726 · doc4.xml · nonDerivative · entry 1 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,674,449 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| September 08, 2021 Filed Sep 8, 2021 22:17 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 10,842 | $29.11 | $315,610.62 |
DisclosureSEC source: 0001209191-21-055200 · doc4.xml · nonDerivative · entry 6 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,688,176 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.185 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 08, 2021 Filed Sep 8, 2021 22:17 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 1,499 | $29.11 | $43,635.89 |
DisclosureSEC source: 0001209191-21-055200 · doc4.xml · nonDerivative · entry 5 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,068 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.185 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 08, 2021 Filed Sep 8, 2021 22:20 UTC |
UBS Oncology Impact Fund L.P.10% owner
MPM BIOIMPACT LLC10% owner
|
SaleCommon Stock | 10,842 | $29.11 | $315,610.62 |
DisclosureSEC source: 0001209191-21-055203 · doc4.xml · nonDerivative · entry 3 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,688,176 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.185 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 16:15 UTC |
Baeuerle PatrickSee Remarks
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0000899243-21-035415 · doc4.xml · derivative · entry 4 Baeuerle Patrick · CIK 0001362054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,114 Underlying: Common Stock · 11,000 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vested on September 1, 2019, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 16:15 UTC |
Baeuerle PatrickSee Remarks
|
SaleCommon Stock | 11,000 | $28.45 | $312,950.00 |
DisclosureSEC source: 0000899243-21-035415 · doc4.xml · nonDerivative · entry 2 Baeuerle Patrick · CIK 0001362054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 30, 2021. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 16:15 UTC |
Baeuerle PatrickSee Remarks
|
Exercise / conversionCommon Stock | 11,000 | $4.30 | $47,300.00 |
DisclosureSEC source: 0000899243-21-035415 · doc4.xml · nonDerivative · entry 1 Baeuerle Patrick · CIK 0001362054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 20:15 UTC |
Trigilio JeffreyChief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0000899243-21-035417 · doc4.xml · derivative · entry 4 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,891 Underlying: Common Stock · 15,000 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares vested on September 8, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 20:15 UTC |
Trigilio JeffreyChief Financial Officer
|
SaleCommon Stock | 9,513 | $28.85 | $274,450.05 |
DisclosureSEC source: 0000899243-21-035417 · doc4.xml · nonDerivative · entry 3 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,250 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 30, 2021. F3 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $28.40 to $29.15. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 20:15 UTC |
Trigilio JeffreyChief Financial Officer
|
SaleCommon Stock | 5,487 | $27.83 | $152,703.21 |
DisclosureSEC source: 0000899243-21-035417 · doc4.xml · nonDerivative · entry 2 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,763 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 30, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $27.40 to $28.38. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 20:15 UTC |
Trigilio JeffreyChief Financial Officer
|
Exercise / conversionCommon Stock | 15,000 | $4.30 | $64,500.00 |
DisclosureSEC source: 0000899243-21-035417 · doc4.xml · nonDerivative · entry 1 Trigilio Jeffrey · CIK 0001838671 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2021 Filed Sep 8, 2021 22:17 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 25,067 | $29.04 | $727,945.68 |
DisclosureSEC source: 0001209191-21-055200 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,699,018 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.22 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 07, 2021 Filed Sep 8, 2021 22:17 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 3,465 | $29.04 | $100,623.60 |
DisclosureSEC source: 0001209191-21-055200 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,567 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.22 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 07, 2021 Filed Sep 8, 2021 22:20 UTC |
UBS Oncology Impact Fund L.P.10% owner
MPM BIOIMPACT LLC10% owner
|
SaleCommon Stock | 25,067 | $29.04 | $727,945.68 |
DisclosureSEC source: 0001209191-21-055203 · doc4.xml · nonDerivative · entry 2 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,699,018 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.22 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| September 07, 2021 Filed Sep 8, 2021 20:15 UTC |
Zawel LeighSee Remarks
|
SaleCommon Stock | 28,118 | $28.95 | $814,016.10 |
DisclosureSEC source: 0000899243-21-035331 · doc4.xml · nonDerivative · entry 1 Zawel Leigh · CIK 0001837456 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,406 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.62 to $29.29. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 22:17 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 12,731 | $29.60 | $376,837.60 |
DisclosureSEC source: 0001209191-21-055200 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,724,085 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 22:17 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 1,760 | $29.60 | $52,096.00 |
DisclosureSEC source: 0001209191-21-055200 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,032 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 22:20 UTC |
UBS Oncology Impact Fund L.P.10% owner
MPM BIOIMPACT LLC10% owner
|
SaleCommon Stock | 12,731 | $29.60 | $376,837.60 |
DisclosureSEC source: 0001209191-21-055203 · doc4.xml · nonDerivative · entry 1 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,724,085 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| September 02, 2021 Filed Sep 2, 2021 21:25 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 15,757 | $29.46 | $464,201.22 |
DisclosureSEC source: 0001209191-21-054517 · doc4.xml · nonDerivative · entry 8 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,736,816 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 02, 2021 Filed Sep 2, 2021 21:25 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 2,178 | $29.46 | $64,163.88 |
DisclosureSEC source: 0001209191-21-054517 · doc4.xml · nonDerivative · entry 7 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,792 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 02, 2021 Filed Sep 2, 2021 21:26 UTC |
UBS Oncology Impact Fund L.P.10% owner
MPM BIOIMPACT LLC10% owner
|
SaleCommon Stock | 15,757 | $29.46 | $464,201.22 |
DisclosureSEC source: 0001209191-21-054518 · doc4.xml · nonDerivative · entry 4 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,736,816 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 21:25 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 5,714 | $29.47 | $168,391.58 |
DisclosureSEC source: 0001209191-21-054517 · doc4.xml · nonDerivative · entry 6 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,752,573 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 21:25 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 790 | $29.47 | $23,281.30 |
DisclosureSEC source: 0001209191-21-054517 · doc4.xml · nonDerivative · entry 5 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,970 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 21:26 UTC |
UBS Oncology Impact Fund L.P.10% owner
MPM BIOIMPACT LLC10% owner
|
SaleCommon Stock | 5,714 | $29.47 | $168,391.58 |
DisclosureSEC source: 0001209191-21-054518 · doc4.xml · nonDerivative · entry 3 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,752,573 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 21:25 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 1,553 | $30.14 | $46,807.42 |
DisclosureSEC source: 0001209191-21-054517 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,758,287 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.01 to $30.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 21:25 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 215 | $30.14 | $6,480.10 |
DisclosureSEC source: 0001209191-21-054517 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,760 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.01 to $30.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 21:25 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 1,285 | $29.43 | $37,817.55 |
DisclosureSEC source: 0001209191-21-054517 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,759,840 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 21:25 UTC |
GADICKE ANSBERTDirector · 10% owner
|
SaleCommon Stock | 177 | $29.43 | $5,209.11 |
DisclosureSEC source: 0001209191-21-054517 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,975 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 21:26 UTC |
UBS Oncology Impact Fund L.P.10% owner
MPM BIOIMPACT LLC10% owner
|
SaleCommon Stock | 1,553 | $30.14 | $46,807.42 |
DisclosureSEC source: 0001209191-21-054518 · doc4.xml · nonDerivative · entry 2 UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,758,287 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.01 to $30.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.direct: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.